Literature DB >> 15198995

Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.

Remko de Pril1, David F Fischer, Marion L C Maat-Schieman, Barbara Hobo, Rob A I de Vos, Ewout R Brunt, Elly M Hol, Raymund A C Roos, Fred W van Leeuwen.   

Abstract

Polyglutamine diseases are characterized by neuronal intranuclear inclusions (NIIs) of expanded polyglutamine proteins, indicating the failure of protein degradation. UBB(+1), an aberrant form of ubiquitin, is a substrate and inhibitor of the proteasome, and was previously reported to accumulate in Alzheimer disease and other tauopathies. Here, we show accumulation of UBB(+1) in the NIIs and the cytoplasm of neurons in Huntington disease and spinocerebellar ataxia type-3, indicating inhibition of the proteasome by polyglutamine proteins in human brain. We found that UBB(+1) not only increased aggregate formation of expanded polyglutamines in neuronally differentiated cell lines, but also had a synergistic effect on apoptotic cell death due to expanded polyglutamine proteins. These findings implicate UBB(+1) as an aggravating factor in polyglutamine-induced neurodegeneration, and clearly identify an important role for the ubiquitin-proteasome system in polyglutamine diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198995     DOI: 10.1093/hmg/ddh188

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  33 in total

Review 1.  Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease.

Authors:  Ashok N Hegde; Sudarshan C Upadhya
Journal:  Biochim Biophys Acta       Date:  2010-08-03

2.  Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.

Authors:  Daniel Alvira; Ruth Naughton; Lavinia Bhatt; Sara Tedesco; William D Landry; Thomas G Cotter
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

3.  Characterizing polyubiquitinated forms of the neurodegenerative ubiquitin mutant UBB+1.

Authors:  Michal Chojnacki; Daoning Zhang; Monika Talarowska; Piotr Gałecki; Janusz Szemraj; David Fushman; Mark A Nakasone
Journal:  FEBS Lett       Date:  2016-11-22       Impact factor: 4.124

4.  BimEL as a possible molecular link between proteasome dysfunction and cell death induced by mutant huntingtin.

Authors:  Rebecca Leon; Nithya Bhagavatula; Onome Ulukpo; Mark McCollum; Jianning Wei
Journal:  Eur J Neurosci       Date:  2010-05-24       Impact factor: 3.386

Review 5.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

Review 6.  Protein quality control in neurodegeneration: walking the tight rope between health and disease.

Authors:  E M Hol; W Scheper
Journal:  J Mol Neurosci       Date:  2007-03-24       Impact factor: 3.444

7.  Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.

Authors:  Haiqun Jia; Ryan J Kast; Joan S Steffan; Elizabeth A Thomas
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

8.  Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.

Authors:  Hyemyung Seo; Woori Kim; Ole Isacson
Journal:  Hum Mol Genet       Date:  2008-07-17       Impact factor: 6.150

9.  Abeta inhibits the proteasome and enhances amyloid and tau accumulation.

Authors:  Bertrand P Tseng; Kim N Green; Julie L Chan; Mathew Blurton-Jones; Frank M LaFerla
Journal:  Neurobiol Aging       Date:  2007-06-01       Impact factor: 4.673

10.  Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutation.

Authors:  Belvin Gong; Catherine Kielar; A Jennifer Morton
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.